{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:56:10Z","timestamp":1790891770666,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012397","name":"Army Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014869","name":"Army Medical University Xinqiao Hospital","doi-asserted-by":"publisher","award":["2023XKRC002"],"award-info":[{"award-number":["2023XKRC002"]}],"id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pccm.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:23:26Z","timestamp":1788780206000},"page":"235-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adoptive cell therapy in lung cancer: progress, challenges, and prospects"],"prefix":"10.1016","volume":"4","author":[{"given":"Jingyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-8512","authenticated-orcid":false,"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pccm.2026.08.002_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pccm.2026.08.002_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18179076","article-title":"Incidence and prevalence analysis of non-small-cell and small-cell lung cancer using administrative data","volume":"18","author":"Ricotti","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.pccm.2026.08.002_bib0003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2026.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0005","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0007","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0008","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","article-title":"Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing","volume":"24","author":"Guo","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0009","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pccm.2026.08.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pccm.2026.08.002_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jtho.2017.10.001","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies","volume":"13","author":"Kiesgen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.pccm.2026.08.002_bib0014","first-page":"6998","article-title":"Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: a case report","volume":"16","author":"Xia","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pccm.2026.08.002_bib0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ijc.35422","article-title":"Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: a phase II study","volume":"157","author":"Zhong","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/pcmedi\/pbz023","article-title":"Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations","volume":"2","author":"Hong","year":"2019","journal-title":"Precis Clin Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0017","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0018","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","article-title":"The next generation of immunotherapies for lung cancers","volume":"22","author":"Zhao","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.trecan.2024.04.003","article-title":"Lifileucel: the first cellular therapy approved for solid tumours","volume":"10","author":"Julve","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0022","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0023","doi-asserted-by":"crossref","DOI":"10.4028\/b-7TThNX","article-title":"TIL therapy in lung cancer: current progress and perspectives","volume":"11","author":"Hu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.pccm.2026.08.002_bib0024","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0025","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0026","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0027","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0028","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0029","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0030","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human Papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0031","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0032","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0033","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","article-title":"A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma","volume":"78","author":"Ratto","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0034","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0035","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040743","article-title":"Adoptive immunotherapy beyond CAR T-cells","volume":"13","author":"Titov","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pccm.2026.08.002_bib0038","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0039","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/CM9.0000000000002991","article-title":"Recent advances and remaining challenges in lung cancer therapy","volume":"137","author":"Barr","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pccm.2026.08.002_bib0040","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pccm.2026.08.002_bib0041","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pccm.2026.08.002_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215840","article-title":"Neoantigen-targeted TCR-T cell therapy for solid tumors: how far from clinical application","volume":"546","author":"Xu","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pccm.2026.08.002_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0044","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.pccm.2026.08.002_bib0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00408-009-9181-3","article-title":"Expression of cancer-testis antigens MAGE-A3\/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration","volume":"187","author":"Kim","year":"2009","journal-title":"Lung"},{"key":"10.1016\/j.pccm.2026.08.002_bib0046","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-466","article-title":"Analysis of GAGE, NY-ESO-1 and SP17 cancer\/testis antigen expression in early stage non-small cell lung carcinoma","volume":"13","author":"Gjerstorff","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003581","article-title":"Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer","volume":"10","author":"Blumenschein","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.pccm.2026.08.002_bib0048","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2026.08.002_bib0049","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene autoleucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.pccm.2026.08.002_bib0050","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/j.annonc.2023.09.2158","article-title":"1019O clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors","volume":"34","author":"Garcia","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0051","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0052","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.pccm.2026.08.002_bib0053","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pccm.2026.08.002_bib0054","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fbioe.2019.00043","article-title":"Engineered cell-based therapeutics: synthetic biology meets immunology","volume":"7","author":"Caliendo","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.782775","article-title":"Chimeric antigen receptor T-cell therapy in lung cancer: potential and challenges","volume":"12","author":"Xiao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0057","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","article-title":"Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer","volume":"59","author":"Feng","year":"2016","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.pccm.2026.08.002_bib0058","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0059","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0060","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pccm.2026.08.002_bib0061","first-page":"xi12","article-title":"35O - phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0062","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1158\/0008-5472.CAN-17-0299","article-title":"Noninvasive interrogation of DLL3 expression in metastatic small cell lung cancer","volume":"77","author":"Sharma","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0063","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0064","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.3390\/cimb45110566","article-title":"Advances in CAR T cell therapy for non-small cell lung cancer","volume":"45","author":"Ma","year":"2023","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0066","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0067","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41590-023-01658-z","article-title":"Harnessing CD3 diversity to optimize CAR T cells","volume":"24","author":"Velasco C\u00e1rdenas","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0068","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3\u03b5 and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0069","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1016\/j.ymthe.2025.08.002","article-title":"Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy","volume":"33","author":"Shukla","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.pccm.2026.08.002_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5191","article-title":"Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors","volume":"13","author":"Liu","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114949","article-title":"TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.pccm.2026.08.002_bib0072","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","article-title":"FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy","volume":"629","author":"Chan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0073","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0074","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","article-title":"Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction","volume":"567","author":"Liu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0076","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","article-title":"Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0077","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.pccm.2026.08.002_bib0078","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0079","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0080","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0081","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0082","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0083","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.pccm.2026.08.002_bib0084","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pccm.2026.08.002_bib0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and anti-tumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0086","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent anti-tumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0087","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0088","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4237","article-title":"Programming tissue-sensing T cells that deliver therapies to the brain","volume":"386","author":"Simic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.pccm.2026.08.002_bib0089","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0091","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0092","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0093","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pccm.2026.08.002_bib0094","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.pccm.2026.08.002_bib0095","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0096","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0097","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.pccm.2026.08.002_bib0098","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0099","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0101","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0102","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pccm.2026.08.002_bib0103","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.pccm.2026.08.002_bib0104","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pccm.2026.08.002_bib0105","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2026.08.002_bib0106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0107","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0108","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.002_bib0109","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B Cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.pccm.2026.08.002_bib0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2026.08.002_bib0111","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pccm.2026.08.002_bib0112","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1182\/blood-2024-208176","article-title":"Targeted lipid nanoparticle delivery of an RNA gene writer in vivo enables generation of CAR-T cells in a humanized house model","volume":"144","author":"Rodriguez","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pccm.2026.08.002_bib0113","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.pccm.2026.08.002_bib0114","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0115","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0116","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0117","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with anti-tumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pccm.2026.08.002_bib0118","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0119","article-title":"CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines","volume":"6","author":"Look","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.pccm.2026.08.002_bib0120","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cac2.70053","article-title":"Harnessing chimeric antigen receptor macrophages against solid tumors","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun"},{"key":"10.1016\/j.pccm.2026.08.002_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111128","article-title":"Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy","volume":"40","author":"Chang","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.pccm.2026.08.002_bib0122","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pccm.2026.08.002_bib0123","article-title":"Sequence and structural determinants of efficacious de novo chimeric antigen receptors","volume":"2025","author":"Chow","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.pccm.2026.08.002_bib0124","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pccm.2025.08.005","article-title":"Chimeric antigen receptor-T cell therapy for lung cancer: the tumor microenvironment bottleneck and remedies to circumvent it","volume":"3","author":"Zhou","year":"2025","journal-title":"Chin Med J Pulm Crit Care Med"}],"container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558826000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558826000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:10:09Z","timestamp":1790889009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772558826000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772558826000472"],"URL":"https:\/\/doi.org\/10.1016\/j.pccm.2026.08.002","relation":{},"ISSN":["2772-5588"],"issn-type":[{"value":"2772-5588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive cell therapy in lung cancer: progress, challenges, and prospects","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Journal Pulmonary and Critical Care Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pccm.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}